Low-density lipoprotein receptor genotype-dependent response to cholesterol lowering by combined pravastatin and cholestyramine in familial hypercholesterolemia

K Kajinami; K Yagi; T Higashikata; A Inazu; J Koizumi; H Mabuchi

doi:10.1016/s0002-9149(98)00230-6

Low-density lipoprotein receptor genotype-dependent response to cholesterol lowering by combined pravastatin and cholestyramine in familial hypercholesterolemia

Am J Cardiol. 1998 Jul 1;82(1):113-7. doi: 10.1016/s0002-9149(98)00230-6.

Authors

K Kajinami¹, K Yagi, T Higashikata, A Inazu, J Koizumi, H Mabuchi

Affiliation

¹ Second Department of Internal Medicine, School of Medicine, Kanazawa University, Japan.

PMID: 9671018
DOI: 10.1016/s0002-9149(98)00230-6

Abstract

We compared the effects of cholesterol-lowering therapy on 2 patient groups genetically defined as heterozygous for familial hypercholesterolemia (FH), 5 with a deletion of exon 15 (FH(Tonami-1)), and 7 with a point mutation at codon 664 (FH(Kanazawa-2)). There were significant differences in both serum and low-density lipoprotein cholesterol reductions between the 2 groups after combination therapy with pravastatin and cholestyramine, and the overall effect of genotype on serial changes in both was significant.

Publication types

Comparative Study
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Anion Exchange Resins / therapeutic use*
Anticholesteremic Agents / therapeutic use*
Bile / metabolism
Cholestyramine Resin / therapeutic use*
Drug Therapy, Combination
Female
Genotype
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Hyperlipoproteinemia Type II / drug therapy*
Hyperlipoproteinemia Type II / genetics*
Male
Middle Aged
Pravastatin / therapeutic use*
Receptors, LDL / genetics*
Treatment Outcome

Substances

Anion Exchange Resins
Anticholesteremic Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Receptors, LDL
Cholestyramine Resin
Pravastatin